Roquefort Investments PLC (ROQ) - Total Liabilities
Based on the latest financial reports, Roquefort Investments PLC (ROQ) has total liabilities worth GBX909.12K GBX (≈ $110.61 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Roquefort Investments PLC net asset momentum to track the company's year-over-year net asset growth rate.
Roquefort Investments PLC - Total Liabilities Trend (2021–2024)
This chart illustrates how Roquefort Investments PLC's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Roquefort Investments PLC to measure how efficiently the company converts operating cash flow to free cash.
Roquefort Investments PLC Competitors by Total Liabilities
The table below lists competitors of Roquefort Investments PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Panamax AG
F:ICP
|
Germany | €365.14K |
|
ICG Longbow Senior Secured UK Property Debt Investments Ltd
LSE:LBOW
|
UK | GBX208.94K |
|
Adventure Box Technology AB
ST:ADVBOX
|
Sweden | Skr15.06 Million |
|
Cambridge Cognition Holdings Plc
LSE:COG
|
UK | GBX9.40 Million |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
Indonesia | Rp754.04 Billion |
|
Trustco Group Holdings
JSE:TTO
|
South Africa | ZAC2.63 Billion |
|
Conygar Investment Co PLC
LSE:CIC
|
UK | GBX59.48 Million |
|
Rua Life Sciences PLC
LSE:RUA
|
UK | GBX1.93 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Roquefort Investments PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Roquefort Investments PLC (ROQ) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roquefort Investments PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roquefort Investments PLC (2021–2024)
The table below shows the annual total liabilities of Roquefort Investments PLC from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX861.73K ≈ $104.85 |
+46.30% |
| 2023-12-31 | GBX589.02K ≈ $71.67 |
+4.89% |
| 2022-12-31 | GBX561.58K ≈ $68.33 |
+17.63% |
| 2021-12-31 | GBX477.43K ≈ $58.09 |
-- |
About Roquefort Investments PLC
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with nov… Read more